The National Institutes of Health is testing pilot initiatives to address the problem of irreproducible scientific results.
Taking down a cellular henchman linked to a cell death pathway relieves symptoms of a lysosomal storage disorder in mice. Researchers hope the pathway could lead to a treatment.
Using the transferrin receptor to deliver therapeutics to the brain is tricky—antibodies that bind too tightly stall in blood vessel cells and shut down transport.
Scientists claim to turn differentiated mouse cells into pluripotent ones with a brief dip in an acid bath—no genetic tweaks necessary.
Combining exome sequencing with gene interaction analysis allowed researchers to identify 18 new genes for an inherited movement disorder. This method could lead to genes linked to other neurodegenerative diseases.
Proteins that interact with the Parkinson’s risk gene LRRK2 point to protein trafficking and degradation as causes of pathogenesis.
Once considered a nuclear homebody, TDP-43 ventures out to accompany mRNAs down axons to nerve terminals where the transcripts can be turned into protein.
Aggressively treating high blood pressure and cholesterol in older adults with diabetes does not prevent cognitive decline, and results in more brain shrinkage.
Live imaging of the mouse brain offers a rare view of α-synuclein dynamics at presynaptic terminals, and raises questions about which form of the protein triggers synaptic dysfunction.
In a cell culture system, astrocytes from people with ALS kill motor neurons. The model could yield more discoveries about the fundamental biology of this disease.
It’s not just for tugging APP around the neuron: The SORLA receptor may also bind Aβ and hasten its demise.
Mutant FUS meddles with RNA splicing and DNA damage repair in transgenic mice that succumb to disease.
Already linked to Alzheimer’s and other neurodegenerative diseases, a TREM2 variant now shows up on the ALS radar, too.
The antidepressant citalopram reduces agitation in Alzheimer’s patients, but caused abnormal heart rhythms at the tested dose.
The FDA has stopped the personal genome sequencing company 23andMe from selling health assessments, saying its tests need validation. What do Alzheimer scientists think?